Coelho Rogerio Vivaldi
CIK 1610381 · PRESIDENT AND CEO · last filed 2026-07-07
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.44M
Companies
6
Total Filings
36
Lifetime Open-Market Net
-$3.69M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CRNX | Director | 19,225 | $83.86 | $1.61M | -$190.5K | 10 | 2026-07-07 |
| VTRS | Director | 45,351 | $17.86 | $810.0K | $0 | 4 | 2026-03-10 |
| Sigilon Therapeutics, Inc. (SGTX) Delisted | PRESIDENT AND CEO | 0 | $22.47 | $0 | $0 | 8 | 2023-08-11 |
| Bioverativ Inc. (BIVV) Delisted | EVP, Chief Global Therapeutics | 0 | — | — | $0 | 5 | 2018-03-08 |
| Spark Therapeutics, Inc. (ONCE) Delisted | Chief Commercial Officer | 20,116 | — | — | -$3.75M | 6 | 2016-07-19 |
| NERV | President and CEO | 5,208 | $4.28 | $22.3K | $250.0K | 1 | 2014-07-09 |
Recent Filings · Page 2 of 4
36 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-06-04 | VTRS | Grant (A) | — | $0 | EDGAR |
| 2023-08-11 | Sigilon Therapeutics, Inc. (SGTX) Delisted | Disp (D) | −12,169 | $0 | EDGAR |
| 2023-07-24 | Sigilon Therapeutics, Inc. (SGTX) Delisted | Exer (M) | +5,528 | $106.4K | EDGAR |
| 2023-06-21 | CRNX | Grant (A) | +6,000 | $0 | EDGAR |
| 2023-06-09 | CRNX | Buy (P) | +5,000 | $110.3K | EDGAR |
| 2023-03-01 | Sigilon Therapeutics, Inc. (SGTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-21 | CRNX | Grant (A) | — | $0 | EDGAR |
| 2022-04-04 | CRNX | Grant (A) | — | $0 | EDGAR |
| 2022-02-22 | Sigilon Therapeutics, Inc. (SGTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-01-10 | CRNX | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.